PALO ALTO, Calif., Jan. 21 /PRNewswire/ -- Cell Biosciences, Inc., a provider of nanoproteomic analysis systems to life science researchers, today announced the launch of its first kits for the analysis of specific oncoproteins on the Firefly(TM) 3000 Protein Analysis System. The new kits are optimized for characterization of proteins in the MEK and ERK families, which play critical roles in cancer cell survival and proliferation. Drug developers have targeted signaling via MEK and ERK with a number of kinase inhibitor anticancer drugs.
The Firefly 3000 system is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which generally precludes protein analysis in precious clinical samples. By using the new analysis kits on the Firefly 3000 system, researchers can obtain detailed profiles of MEK and ERK signaling in as few as 25 cells. Subtle effects of kinase inhibitor drugs on MEK and ERK phosphorylation can be studied in cancer cells and solid tumor samples.
"We developed these oncoprotein analysis kits in response to strong interest from our cancer research customers," said Wilhelm Lachnit, Ph.D., Vice President of Research and Development. "They enable robust analysis of MEK and ERK phosphoprotein signaling, and provide a unique window into the specific actions of kinase inhibitor drugs in limited samples."
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems and assays for the measurement of phosphoprotein signaling and activation in extremely small biological samples. Our company's lead product is a capillary-based nano-fluidic immunoassay platform that provides quantitative and reproducible data on key signaling pathways in precious biological samples, such as small tumor biopsies and stem cells. Cell Biosciences is located in Palo Alto, California.
|SOURCE Cell Biosciences, Inc.|
Copyright©2009 PR Newswire.
All rights reserved